The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.
Allan Lipton
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Karim Fizazi
Consultant or Advisory Role - Amgen
Alison Stopeck
Consultant or Advisory Role - Amgen; Genentech
Honoraria - Amgen
David H. Henry
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Matthew Raymond Smith
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Neal D. Shore
Consultant or Advisory Role - Amgen
Miguel Martin
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Amgen; GlaxoSmithKline
Saroj Vadhan-Raj
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Other Remuneration - Amgen
Kefei Zhou
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Arun Balakumaran
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ada H. Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen